Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Jpn J Infect Dis ; 61(4): 307-9, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18653976

ABSTRACT

From May 2004 to October 2006, a prospective study was carried out in Dakar, Senegal, to update information about the antimicrobial susceptibility of Shigella spp. isolated from stool specimens. Among the 165 non-duplicate strains collected, 81 (49%) were identified as Shigella flexneri, 75 (45%) as Shigella sonnei, 5 (3%) as Shigella boydii, and 4 (2%) as Shigella dysenteriae. Disk diffusion testing revealed that the majority of isolates were resistant to sulphonamides, trimethoprim-sulfamethoxazole, streptomycin, and tetracycline (respective overall resistance rates: 90, 90, 96, and 94%). More than half of the S. flexneri isolates were resistant to amoxicillin, amoxicillin-clavulanic acid, and chloramphenicol (respective resistance rates: 59, 58, and 52%), and almost all of the S. sonnei isolates were susceptible to these antimicrobials (respective resistance rates: 4, 1, and 4%). Only one isolate (belonging to the species S. sonnei) was resistant to nalidixic acid and displayed reduced susceptibility to ciprofloxacin.


Subject(s)
Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial , Dysentery, Bacillary , Shigella/classification , Shigella/drug effects , Adolescent , Adult , Aged , Child , Child, Preschool , Disk Diffusion Antimicrobial Tests , Dysentery, Bacillary/epidemiology , Dysentery, Bacillary/microbiology , Feces/microbiology , Humans , Infant , Middle Aged , Senegal/epidemiology , Shigella/isolation & purification , Shigella boydii/drug effects , Shigella boydii/isolation & purification , Shigella dysenteriae/drug effects , Shigella dysenteriae/isolation & purification , Shigella flexneri/drug effects , Shigella flexneri/isolation & purification , Shigella sonnei/drug effects , Shigella sonnei/isolation & purification , Species Specificity
2.
Int J Antimicrob Agents ; 29(4): 397-401, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17224260

ABSTRACT

In this study, topoisomerase mutations in ciprofloxacin-resistant and -susceptible Campylobacter jejuni were analysed by DNA sequencing. In certain ciprofloxacin-resistant C. jejuni, the mechanism of resistance was complex. The Thr86-Ala substitution in the GyrA protein appears to play a role in increasing the minimum inhibitory concentration of nalidixic acid only. In addition, isolates with this amino acid change and those resistant to quinolones but lacking a mutation in the GyrA quinolone resistance-determining region could be derived from two different clones. Based on gyrA and gyrB polymorphisms, C. jejuni isolates from the Dakar region of Senegal appeared to be less diverse than those from other countries. Moreover, C. jejuni isolates in Senegal appeared to differ from European isolates by lack of a silent mutation at codon 120 of the gyrA gene.


Subject(s)
Campylobacter jejuni/drug effects , Campylobacter jejuni/genetics , DNA Gyrase/genetics , Drug Resistance, Bacterial/genetics , Fluoroquinolones/pharmacology , Animals , Campylobacter Infections/drug therapy , Campylobacter Infections/epidemiology , Campylobacter Infections/microbiology , DNA Gyrase/drug effects , DNA Topoisomerase IV/drug effects , DNA Topoisomerase IV/genetics , Europe , Microbial Sensitivity Tests , Mutation , Nalidixic Acid/pharmacology , Polymorphism, Genetic , Senegal/epidemiology
3.
Res Microbiol ; 158(2): 138-42, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17258435

ABSTRACT

We used the multilocus sequence typing (MLST) method to study the genetic diversity of Campylobacter coli isolated from chickens in Senegal, and to check the presence of genetic exchange with Campylobacter jejuni. In addition, we assessed the resistance of the isolates to ciprofloxacin and nalidixic acid, and their gyrA sequences. MLST revealed a low level of diversity and the absence of lineages among C. coli isolates. In addition, an exchange of alleles with C. jejuni was found. Twenty percent of the ciprofloxacin-resistant isolates lacked mutations within the quinolone resistance-determining region (QRDR) of GyrA. There was no link between quinolone resistance and sequence type (ST).


Subject(s)
Campylobacter coli/drug effects , Campylobacter coli/genetics , Chickens/microbiology , Quinolones/pharmacology , Alleles , Animals , Anti-Infective Agents/pharmacology , Campylobacter jejuni/genetics , Ciprofloxacin/pharmacology , DNA Gyrase/genetics , Drug Resistance, Bacterial , Genetic Variation , Nalidixic Acid/pharmacology , Polymerase Chain Reaction , Senegal
4.
J Infect Dev Ctries ; 1(3): 263-8, 2007 Dec 01.
Article in English | MEDLINE | ID: mdl-19734603

ABSTRACT

BACKGROUND: Data regarding the evolution of antimicrobial resistance are needed to suggest appropriate empirical treatment of urinary tract infections (UTI) in developing countries. To assess the antimicrobial susceptibility of Escherichia coli, the predominant pathogen in community-acquired UTI, a prospective multicenter study was carried out in Dakar, Senegal. METHODOLOGY: From February 2004 to October 2006, 1010 non-duplicate E. coli strains were collected from four centres. Antimicrobial susceptibility testing was performed using disk diffusion method according to the recommendations of the CA-SFM (2004). RESULTS: Most of the isolates were resistant to amoxicillin (73.1%), amoxicillin-clavulanic acid (67.5%), cephalothin (55.8%), and trimethoprim/sulfamethoxazole (68.1%). Extended spectrum beta-lactamase was detected in 38 strains. The overall resistance rates to nalidixic acid, norfloxacin and ciprofloxacin were 23.9%, 16.4% and 15.5%, respectively. Most of the strains were susceptible to gentamicin, nitrofurantoin and fosfomycin (respective susceptibility rates, 93.8%, 89.9%, and 99.3%). During this period, a significant decrease in sensitivity was observed for cephalothin, fluoroquinolones and trimethoprim/sulfamethoxazole (p<0.001). CONCLUSIONS: These data suggest that trimethoprim/sulfamethoxazole may no longer be used as empirical treatment for community-acquired UTI in Dakar. In order to preserve the activity of fluoroquinolones for future years, alternatives such as fosfomycin or nitrofurantoin should be considered.


Subject(s)
Drug Resistance, Multiple, Bacterial , Escherichia coli Infections/microbiology , Escherichia coli/drug effects , Urinary Tract Infections/microbiology , Adolescent , Adult , Community-Acquired Infections/drug therapy , Community-Acquired Infections/epidemiology , Community-Acquired Infections/microbiology , Escherichia coli/isolation & purification , Escherichia coli Infections/drug therapy , Escherichia coli Infections/epidemiology , Female , Humans , Incidence , Male , Microbial Sensitivity Tests , Middle Aged , Outpatients , Pregnancy , Prospective Studies , Senegal/epidemiology , Urinary Tract Infections/drug therapy , Urinary Tract Infections/epidemiology , Young Adult
5.
Appl Environ Microbiol ; 72(5): 3309-13, 2006 May.
Article in English | MEDLINE | ID: mdl-16672471

ABSTRACT

We used the multilocus sequence typing (MLST) method to evaluate the genetic diversity of 46 Campylobacter jejuni isolates from chickens and to determine the link between quinolone resistance and sequence type (ST). There were a total of 16 ST genotypes, and the majority of them belonged to seven clonal complexes previously identified by using isolates from human disease. The ST-353 complex was the most common complex, whereas the ST-21, ST-42, ST-52, and ST-257 complexes were less well represented. The resistance phenotype varied for each ST, and the Thr-86-Ile substitution in the GyrA protein was the predominant mechanism of resistance to quinolone. Nine of the 14 isolates having the Thr-86-Ile substitution belonged to the ST-353 complex. MLST showed that the emergence of quinolone resistance is not related to the diffusion of a unique clone and that there is no link between ST genotype and quinolone resistance. Based on silent mutations, different variants of the gyrA gene were shown to exist for the same ST. These data provide useful information for understanding the epidemiology of C. jejuni in Senegal.


Subject(s)
Anti-Infective Agents/pharmacology , Campylobacter jejuni/drug effects , Drug Resistance, Bacterial , Genetic Variation , Poultry/microbiology , Quinolones/pharmacology , Animals , Campylobacter jejuni/classification , Campylobacter jejuni/genetics , Campylobacter jejuni/isolation & purification , Chickens/microbiology , Ciprofloxacin/pharmacology , DNA Gyrase/genetics , Microbial Sensitivity Tests , Mutation , Nalidixic Acid/pharmacology , Senegal
SELECTION OF CITATIONS
SEARCH DETAIL
...